Clinical Trials List
2014-05-01 - 2029-12-31
Phase III
Recruiting6
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 羅喬 Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
- 林柏翰 Division of General Internal Medicine
- 林季宏 Division of Hematology & Oncology
- MING-YANG WANG Division of General Surgery
- 蔡立威 Division of General Surgery
- 郭文宏 Division of General Surgery
- Wei-Wu Chen Division of Hematology & Oncology
- 林璟宏 Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 沈士哲 Division of General Surgery
- Chi-Chang Yu Division of General Surgery
- Yung-Chang Lin Division of Hematology & Oncology
- Wen-Chi Shen Division of Hematology & Oncology
- Hsien-Kun Chang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yao-Chung Wu Division of General Surgery
- Liang-Chih Liu Division of General Surgery
- Chih-Jung Chen Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 邱仁輝 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- Yi-Fang Tsai Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Sin-Syue Li Division of General Internal Medicine
- Yao-Lung Kuo Division of General Surgery
- Ya-Ting Hsu Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
1800 participants
